CTL Amedica is unveiling its RODIN™ Transforaminal Expandable Lumbar Interbody Fusion System.
FDA-cleared and in beta launch, RODIN is a horizontally expandable, minimally invasive interbody implant made of titanium. At a 6mm cross-sectional width, non-deployed, it offers one of the smallest collapsed footprints of any expandable on the market. With its horizontally expanding capabilities, convex surfaces and lordotic offerings, RODIN accomplishes a stable and impressive ALIF footprint through an MIS posterior approach.
CTL Amedica will launch RODIN™ with a long term (> 10-year follow-up) clinical series with a 98.5% clinical and radiographic fusion rate and an animal study showing 100% fusion throughout the entire series, with post study CT scan and histologic confirmation.
CTL Amedica is unveiling its RODIN™ Transforaminal Expandable Lumbar Interbody Fusion System.
FDA-cleared and in beta launch, RODIN is a horizontally expandable, minimally invasive interbody implant made of titanium. At a 6mm cross-sectional width, non-deployed, it offers one of the smallest collapsed footprints of any expandable on the...
CTL Amedica is unveiling its RODIN™ Transforaminal Expandable Lumbar Interbody Fusion System.
FDA-cleared and in beta launch, RODIN is a horizontally expandable, minimally invasive interbody implant made of titanium. At a 6mm cross-sectional width, non-deployed, it offers one of the smallest collapsed footprints of any expandable on the market. With its horizontally expanding capabilities, convex surfaces and lordotic offerings, RODIN accomplishes a stable and impressive ALIF footprint through an MIS posterior approach.
CTL Amedica will launch RODIN™ with a long term (> 10-year follow-up) clinical series with a 98.5% clinical and radiographic fusion rate and an animal study showing 100% fusion throughout the entire series, with post study CT scan and histologic confirmation.
Copy to clipboard 
